Dapzura Rt is owned by Baxter Hlthcare Corp.
Dapzura Rt contains Daptomycin.
Dapzura Rt has a total of 1 drug patent out of which 0 drug patents have expired.
Dapzura Rt was authorised for market use on 25 January, 2022.
Dapzura Rt is available in powder;intravenous dosage forms.
Dapzura Rt can be used as method of treating a bacterial infection by administering a reconstituted solid formulation of daptomycin containing 31.0 to 59.4% wt total mannitol and sorbitol.
The generics of Dapzura Rt are possible to be released after 11 March, 2041.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US11173189||BAXTER HLTHCARE CORP||Daptomycin formulations containing a combination of sorbitol and mannitol|| |
(18 years from now)
Market Authorisation Date: 25 January, 2022
Treatment: Method of treating a bacterial infection by administering a reconstituted solid formulation of daptomycin containing 31.0 to 59.4% wt total mannitol and sorbitol
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic